Provenge Wins In Phase III; Will Dendreon Need to Confirm The IMPACT?
This article was originally published in The Pink Sheet Daily
Executive Summary
Prostate cancer vaccine’s high demand, SPA could help dodge second-study tradition despite iffy history
You may also be interested in...
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
Dendreon Raises $230 Million To Fund Filing And Anticipated Launch Of Provenge
With strong overall survival data in hand for its prostate cancer vaccine, Seattle biotech takes advantage of increased investor interest.